医疗特长：目前主要从事肿瘤微创介入治疗，涵盖原发性及转移性肝癌、肺癌、胆管癌、胰腺癌及盆腔肿瘤、骨转移瘤等多种肿瘤的介入诊疗（包括动脉灌注化疗与栓塞、氩氦刀冷冻、射频、微波消融、粒子与支架植入、输液港植入、穿刺活检等），及肿瘤分子靶向与免疫治疗。

教育及工作经历：

2017年获中山大学医学博士学位，同年就职于中山大学附属第一医院肿瘤介入科，从事肿瘤介入方面工作。曾荣获2023年度“中山大学附属第一医院本科教学优秀教师”称号，并在2024年“中山大学附属第一医院青年教师授课大赛”中荣获一等奖。

社会任职：

现任亚洲冷冻治疗学会第七届委员会委员、广东省健康管理协会脂肪肝多学科诊治专业会委员及广东省中西结合医学肿瘤介入治疗专业委员会委员。

科研情况：

主要研究方向为肝癌综合治疗的临床与基础研究。近年以第一作者在JAMA oncology、Radiol Med、J Cancer Res Clin等高质量SCI杂志上发表论文13篇，单篇最高影响因子为24.79。主持国家自然科学基金青年项目1项及省部级项目3项，参与国家级及省部级项目多项。曾参与获得广东省科技进步奖二等奖及中国抗癌协会科技奖二等奖。

论著：

[1]Fan W, Zhu B, Chen S, Wu Y, et al. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial[J]. JAMA Oncol. 2024 Aug 1;10(8):1047-1054.

[2]Huang K, Liu H, Wu Y, et al. Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors[J]. Radiol Med. 2024 Nov;129(11):1597-1610.

[3]Huang K, Wu Y, Fan W, et al. Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE[J]. J Cancer Res Clin Oncol. 2023 Oct;149(13):11247-11261.

[4]Tang Y, Wu Y, Xue M, et al. A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma[J]. J Oncol. 2022 Jan 24;2022:3822773.

[5]Xue M, Wu Y, Zhu B, et al. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study[J]. Am J Cancer Res. 2021 Dec 15;11(12):6107-6118.

[6]Wu YQ, Fan WZ, Xue M, et al. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization[J]. Clin Transl Oncol. 2020 Jan;22(1):70-80.

[7]Ye J, Wu Y, Li M, et al. Keratin 8 Mutations Were Associated With Susceptibility to Chronic Hepatitis B and Related Progression[J]. J Infect Dis. 2020 Jan 14;221(3):464-473.

[8]Zhu B, Wu Y, Niu L, et al. Silencing SAPCD2 Represses Proliferation and Lung Metastasis of Fibrosarcoma by Activating Hippo Signaling Pathway[J]. Front Oncol. 2020 Dec 15;10:574383.

[9]Xue M, Wu Y, Fan W, et al. Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma[J]. Cancer Res Treat. 2020 Jul;52(3):925-937.

[10]Wu Y, Fan W, Xue M, et al. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization[J]. Oncologist. 2019 Dec;24(12):e1489-e1495.

[11]Fan W, Wu Y, Lu M, et al. A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):451-459.

[12]Ye J, Wu Y, Li F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction[J]. Therap Adv Gastroenterol. 2019 Sep 26;12:1756284819879047.

[13]Wu Y, Zheng S, Yao J, et al. Decreased expression of protocadherin 20 is associated with poor prognosis in hepatocellular carcinoma[J]. Oncotarget. 2017 Jan 10;8(2):3018-3028.